Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice.

Trial Profile

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Mar 2010 Planned number of patients changed from 1650 to 704 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top